Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.

Date publication

septembre 2000

Journal

Cytometry

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MERLIN Jean-Louis

Tous les auteurs :
Merlin JL, Bour-Dill C, Marchal S, Ramacci C, Poullain MG, Giroux B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/10942898

Résumé

S9788 and PSC833 were developped as P-glycoprotein (Pgp) blockers and found to act additionally on daunorubicin subcellular distribution, involving different putative targets. On this basis, combinations of S9788 and PSC833 were evaluated in Pgp-expressing MCF7(DXR) cells in which we recently demonstrated that daunorubicin was sequestered in Golgi vesicles (Bour-Dill et al.: Cytometry, 39: 16-25, 2000).

Mots clés

ATP-Binding Cassette Transporters, genetics, Adenocarcinoma, Antibiotics, Antineoplastic, pharmacokinetics, Antineoplastic Agents, pharmacology, Biological Transport, drug effects, Breast Neoplasms, Cyclosporins, pharmacology, DNA Primers, Daunorubicin, pharmacokinetics, Dose-Response Relationship, Drug, Drug Resistance, Multiple, genetics, Drug Resistance, Neoplasm, genetics, Flow Cytometry, Gene Expression Regulation, Neoplastic, drug effects, Golgi Apparatus, drug effects, Humans, Microscopy, Fluorescence, Multidrug Resistance-Associated Proteins, Neoplasm Proteins, genetics, P-Glycoprotein, antagonists & inhibitors, Phenotype, Piperidines, pharmacology, Triazines, pharmacology, Tumor Cells, Cultured, Vault Ribonucleoprotein Particles, genetics, beta 2-Microglobulin, genetics

Référence

Cytometry. 2000 Sep;41(1):62-72